STC2 inhibitors belong to a distinctive class of chemical compounds that specifically target the Stanniocalcin 2 (STC2) protein. The STC2 protein is a secreted glycoprotein that plays a crucial role in various cellular processes, including cell proliferation, apoptosis, and cellular stress responses. Inhibitors designed to modulate the activity of STC2 operate by interfering with its normal function, ultimately impacting the signaling pathways in which this protein is involved.
The development of STC2 inhibitors is rooted in a deep understanding of the molecular mechanisms underlying the actions of STC2, making them a subject of interest in the field of molecular biology and biochemistry.These inhibitors are meticulously designed molecules that exhibit a high degree of specificity for STC2, aiming to disrupt its interactions with cellular components or impede its enzymatic activity. By doing so, STC2 inhibitors may exert a regulatory effect on downstream cellular processes, influencing critical events such as cell cycle progression and responses to environmental stressors. The design and synthesis of STC2 inhibitors involve a comprehensive exploration of the protein's structure and function, guiding the creation of compounds that can selectively bind to the target site on STC2. T
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is part of the ERK/MAPK pathway. By inhibiting MEK, PD98059 can indirectly inhibit STC2. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor. It can indirectly inhibit STC2 by blocking the PI3K/Akt pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor. By inhibiting PI3K, it can prevent the activation of the PI3K/Akt pathway and thereby indirectly inhibit STC2. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 (AG490) is a JAK2 inhibitor. By inhibiting JAK2, it can prevent the activation of the JAK/STAT pathway and thereby indirectly inhibit STC2. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is another JAK inhibitor, specifically inhibiting JAK1 and JAK2, which can indirectly inhibit STC2 via the JAK/STAT pathway. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor, which can indirectly inhibit STC2 by acting on the ERK/MAPK pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is another selective inhibitor of MEK1/2, thereby indirectly inhibiting STC2 via the ERK/MAPK pathway. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
CAL-101 (Idelalisib) is a PI3Kδ inhibitor, which can indirectly inhibit STC2 by acting on the PI3K/Akt pathway. | ||||||
IPI 145 | 1201438-56-3 | sc-488318 | 5 mg | $317.00 | ||
Duvelisib is a PI3Kγ inhibitor, which can indirectly inhibit STC2 by acting on the PI3K/Akt pathway. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib is a JAK1/2 inhibitor, which can indirectly inhibit STC2 by acting on the JAK/STAT pathway. | ||||||